Lv2
160 积分 2026-05-09 加入
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
9天前
已完结
[Cancer incidence and mortality across diverse geographical regions in China, 2024]
9天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
23天前
已完结
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
23天前
已完结
Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials
27天前
已关闭
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
1个月前
已完结
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
1个月前
已完结
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
1个月前
已完结
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
1个月前
已关闭
Overweight, inflammation of normal colorectal mucosa, and cancer risk
1个月前
已关闭
皖公网安备34019202002308
